Logos Global Management’s Xenon Pharmaceuticals XENE Stock Holding History

Logos Global Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.2M	Hold	450,000	–	–	1.17%	28
2026 Q1	$26.2M	Buy	+450,000	New	+$20.7M	1.31%	26
2025 Q2	–	Sell	-650,000	Closed	-$21.8M	–	62
2025 Q1	$21.8M	Buy	+650,000	New	+$24.7M	3.88%	7
2024 Q3	–	Sell	-375,000	Closed	-$14.6M	–	70
2024 Q2	$14.6M	Buy	+375,000	New	+$15M	1.18%	25
2024 Q1	–	Sell	-150,000	Closed	-$6.91M	–	72
2023 Q4	$6.91M	Sell	150,000 -300,000	-67%	-$10.6M	0.64%	36
2023 Q3	$15.4M	Buy	450,000 +175,000	+64%	+$6.55M	2.05%	17
2023 Q2	$10.6M	Sell	275,000 -625,000	-69%	-$24.8M	1.44%	22
2023 Q1	$32.2M	Hold	900,000	–	–	4.61%	6
2022 Q4	$35.5M	Buy	900,000 +400,000	+80%	+$14.6M	4.16%	7
2022 Q3	$18.1M	Buy	+500,000	New	+$18M	2.22%	17

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Logos Global Management's XENE Position: Q2 2026 in Review

Logos Global Management held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 450,000 shares worth $27.2M. The position accounts for 1.17% of the portfolio, ranked #28.

Logos Global Management first reported a position in XENE in Q3 2022 and has held it in 10 quarters since. The position peaked at $35.5M in Q4 2022. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Logos Global Management held 450,000 shares of Xenon Pharmaceuticals worth $27.2M as of Q2 2026.
Logos Global Management left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up 1.17% of Logos Global Management's portfolio in Q2 2026, its #28 holding.
Logos Global Management first reported a position in Xenon Pharmaceuticals in Q3 2022 and has held it in 10 quarters since.
Logos Global Management's Xenon Pharmaceuticals position peaked at $35.5M in Q4 2022.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.